XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended
Aug. 01, 2023
May 31, 2023
May 01, 2023
Apr. 04, 2023
Apr. 03, 2023
Mar. 29, 2023
Feb. 05, 2020
Feb. 16, 2018
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Aug. 31, 2022
Feb. 14, 2020
Class of Stock [Line Items]                          
Term of orphan drug exclusivity     7 years                    
Quarterly net revenue target for royalty financing           $ 25,000              
Ordinary shares, nominal value (in dollars per share)   $ 0.01     $ 0.01       $ 0.01   $ 0.01    
Aggregate net proceeds from stock offering         $ 134,151                
ADSs, conversion ratio   11618.46%           9269.56%          
Number of ADSs delivered upon conversion (in shares)   12,347                      
Aggregate amount of conversion   $ 1,470                      
Subsequent Event                          
Class of Stock [Line Items]                          
Royalty financing $ 30,000                        
Ordinary shares                          
Class of Stock [Line Items]                          
Shares sold in offering (in shares)         12,205,000                
Series B Non-Voting Convertible Preferred Shares                          
Class of Stock [Line Items]                          
Shares sold in offering (in shares)         4,706,000                
2020 Shelf Registration Statement                          
Class of Stock [Line Items]                          
Sales agent commission, as a percent of aggregate gross sales proceeds             3.00%            
Maximum aggregate offering price of ADSs under shelf registration                         $ 50,000
2022 Shelf Registration Statement                          
Class of Stock [Line Items]                          
Maximum aggregate offering price of ADSs under shelf registration                       $ 100,000  
At-The-Market Offering Program                          
Class of Stock [Line Items]                          
Aggregate net proceeds from stock offering                 $ 11,913        
Remaining authorized aggregate offering price under shelf registration                 $ 96,064        
At-The-Market Offering Program | American Depositary Shares                          
Class of Stock [Line Items]                          
Shares sold in offering (in shares)                 1,564,000        
Maximum                          
Class of Stock [Line Items]                          
Royalty financing           $ 75,000              
4.50% Exchangeable Senior Notes Due October 2023                          
Class of Stock [Line Items]                          
Interest rate                   4.50%      
4.50% Exchangeable Senior Notes Due October 2023 | Senior Notes                          
Class of Stock [Line Items]                          
Long-term debt       $ 21,187         $ 21,187 $ 117,375 $ 117,375    
Interest rate                 4.50%        
Debt exchanged       $ 96,188                  
April 2027 Notes                          
Class of Stock [Line Items]                          
Interest rate       6.00%                  
April 2027 Notes | Senior Notes                          
Class of Stock [Line Items]                          
Long-term debt       $ 106,268                  
Debt exchanged   $ 106,268                      
Aggregate amount of conversion       $ 106,268